2022

Combined Kdm6a and Trp53 deficiency drives the development of squamous cell skin cancer in mice.
Shea LK*, Akhave NS*, Sutton LA, Compton LA, York C, Ramakrishnan SM, Miller CA, Wartman LD, Chen DY. J Invest Dermatol (2022) PMID: 36055401.

Somatic Dnmt3a inactivation leads to slow, canonical DNA methylation loss in murine hematopoietic cells.
Smith AM, Verdoni AM, Abel HJ, Chen DY, Ketkar S, Leight ER, Miller CA, Ley TJ. iScience (2022). PMID: 35313694.

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
Lozano AX, Chaudhuri AA, Nene A, Bacchiocchi A, Earland N, Vesely MD, Usmani A, Turner BE, Steen CB, Luca BA, Badri T, Gulati GS, Vahid MR, Khameneh F, Harris PK, Chen DY, Dhodapkar K, Sznol M, Halaban R, Newman AM. Nat Med (2022) PMID: 35027754.

2018-2021

Functional and epigenetic phenotypes of humans and mice with DNMT3A overgrowth syndrome.
Smith AM, LaValle TA, Shinawi M, Ramakrishnan SM, Abel HJ, Hill CA, Kirkland NM, Retting MP, Helton NM, Heath SE, Ferraro F, Chen DY, Adak S, Semenkovich CF, Christian DL, Martin JR, Gabel HW, Miller CA, Ley TJ. Nat Commun (2021) PMID: 34315901.

Dnmt3a deficiency in the skin causes focal, canonical DNA hypomethylation and a cellular proliferation phenotype.
Chen DY, Ferguson IM, Braun KA, Sutton LA, Ramakrishnan SM, Helton NM, Smith AM, Miller CA, Ley TJ. Proc Natl Acad Sci (2021) PMID: 33846253.

Remethylation of Dnmt3a−/− hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing.
Ketkar S, Verdoni AM, Smith AM, Bangert CV, Leight E, Chen DY, Brune MK, Helton NM, Hoock M, George DR, Fronick C, Fulton RS, Petti AA, Spencer DH, Miller CA, Ley TJ. Proc Natl Acad Sci (2020) PMID: 31996479.

A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing.
Petti A, Williams SR, Miller CA, Fiddes IT, Srivatsan SN, Chen DY, Fronick CC, Fulton RS, Church DM, Ley TJ. Nat Commun (2019) PMID: 31413257.

DNMT3AR882-associated hypomethylation is maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line.
Chen DY, Christopher M, Helton N, Ferguson I, Ley TJ, Spencer DH. Blood Cancer J (2018) PMID: 29618788.